Cargando…

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy

BACKGROUND: This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns. METHODS: Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Info...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Esra, S. Cilli, Ali, Yazici, Ahmet B., Baysan, Hayriye, Ince, Mustafa, Bosgelmez, Sukriye, Bilgic, Serkan, Aslan, Betul, Erol, Atila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633702/
https://www.ncbi.nlm.nih.gov/pubmed/29081826
http://dx.doi.org/10.2174/1745017901713010092
Descripción
Sumario:BACKGROUND: This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns. METHODS: Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Information about their medications and sociodemographic data was recorded through face-to-face interviews and supporting information about their drug use patterns was obtained from their relatives/caregivers/nurse. The Clinical Global Impression Scale (severity of illness) and the General Assessment of Functionality scales were also administered. RESULTS: Patients with schizophrenia used 2.0 ± 0.81 antipsychotics daily and 3.52 ± 2.55 pills (1–18). Seventy-one percent of the patients used two or more kinds of psychotropic drugs. The most frequently used antipsychotics were quetiapine, a second generation antipsychotic, and haloperidol, a typical antipsychotic. Clinical severity, regular visits to a CCS and use of depot antipsychotics were independent predictors for polypharmacy. CONCLUSION: The rate of polypharmacy use is high in Turkey. There are multiple risk factors related with polipharmacy. New studies should focus risk factors for preventing polypharmacy.